GILD vs NVO: Gilead Sciences and Novo Nordisk A/S compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Gilead Sciences is the larger company, worth $184.1B, close to Novo Nordisk A/S's $161.1B.
- Gilead Sciences grew revenue faster over the last year (+10.2% vs +6.4%).
- Novo Nordisk A/S keeps more of each dollar of revenue as operating profit (41.3% vs -8.2%).
- On earnings, Novo Nordisk A/S is the cheaper stock (8.5x vs 20.2x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | GILD | NVO |
|---|---|---|
| Market cap | $184.1B | $161.1B |
| Share price | $151.17 | $38.64 |
| Revenue (last fiscal year) | $29.4B | $309.1B |
| Free cash flow (last fiscal year) | $9.5B | $29.0B |
| Revenue growth, last year | +10.2% | +6.4% |
| Revenue growth per year, last 5 fiscal years | +1.9% | +21.7% |
| Operating margin | -8.2% | 41.3% |
| Net margin | -10.6% | 33.1% |
| Return on equity | -27.4% | 52.8% |
| P/E (trailing) | 20.2x | 8.53x |
| Price / free cash flow | 19.5x | 5.56x |
| EV / EBITDA | — | 7.80x |
| FCF growth the price implies | 4.6% | — |
| Dividend yield | 2.2% | 5.0% |
| Debt / equity | 3.18x | 1.80x |
| Fundamental grade | D | B |
| Superinvestors holding it | 7 | 9 |
| Insider purchases, last 12 months | 4 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Gilead Sciences
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $27.3B | $10.8B | 36.3% |
| 2022 | $27.3B | $8.3B | 26.9% |
| 2023 | $27.1B | $7.4B | 28.0% |
| 2024 | $28.8B | $10.3B | 5.8% |
| 2025 | $29.4B | $9.5B | 34.0% |
Novo Nordisk A/S
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $140.8B | $47.6B | 41.7% |
| 2022 | $177.0B | $64.1B | 42.3% |
| 2023 | $232.3B | $70.0B | 44.2% |
| 2024 | $290.4B | $69.7B | 44.2% |
| 2025 | $309.1B | $29.0B | 41.3% |
Where the revenue comes from
Gilead Sciences · by products, 2025
Biktarvy$14.3B49%
Descovy$2.8B9%
Genvoya$1.5B5%
Yescarta$1.5B5%
Trodelvy$1.4B5%
Sofosbuvir/Velpatasvir$1.3B4%
Novo Nordisk A/S · by segments, 2025
Obesity and Diabetes care$289.5B94%
Rare disease$19.6B6%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open GILD in InvestinglyQuestions
Which is bigger, Gilead Sciences or Novo Nordisk A/S?
Gilead Sciences (GILD), at $184.1B against $161.1B.
Is GILD or NVO cheaper?
By trailing P/E, Novo Nordisk A/S (8.53x) is cheaper than Gilead Sciences (20.2x). A lower multiple can also mean the market expects less growth.
Which grows faster, GILD or NVO?
Gilead Sciences: revenue grew +10.2% over the last year, against +6.4%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.